A Phase II Trial of Combination Treatment With Vorinostat, Bortezomib and Dexamethasone in Patients With Relapsed and Relapsed Refractory Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Vorinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MUK four
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 16).
- 01 Mar 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 09 Feb 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2011-005361-20).